ASH 2025 update supports renewed strategy

Mendus has presented incremental clinical data for vididencel at the American Society of Hematology (ASH) 67th Annual Meeting, involving long-term follow-up for the ADVANCE II trial. This study is testing the ability of the candidate to prolong survival in acute myeloid leukaemia (AML) as a maintenance therapy. The data showed that at a median follow-up of 55 months, 13/20 patients treated with vididencel were alive, with eight patients having passed the five-year follow-up, and overall survival at 63%. (The prior update was at a median follow-up of 48 months, where 13/20 patients were alive, with five having reached the five-year follow-up). Immunological data tracked with survival, consistent with prior readouts, adding further confide...